New eczema pill shows promise in early safety trial

NCT ID NCT06345404

Completed Symptom relief Sponsor: Corvus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested an experimental drug called soquelitinib in 82 adults with moderate to severe atopic dermatitis (eczema). The main goal was to check safety and tolerability, while also looking for signs of symptom improvement. Participants received either the drug or a placebo, and researchers monitored side effects and changes in eczema severity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: soquelitinib (also known as CPI-818)
What this could lead to: If it works, this could point toward a new oral treatment option for people with moderate to severe eczema that is not controlled by current therapies.
What could go wrong: This is a very early Phase 1 trial focused on safety, not proof of effectiveness. The small size and lack of long-term data mean it may not lead to a viable treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atopic eczema

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ATOPIC DERMATITIS

Contacts and locations

Locations

Clinical Site 1

Camp Hill, Pennsylvania, 17011, United States
Clinical Site 10

Castle Rock, Colorado, 80109, United States
Clinical Site 11

Brooklyn, New York, 11203, United States
Clinical Site 12

New York, New York, 10075, United States
Clinical Site 13

Pomona, California, 91767, United States
Clinical Site 14

San Antonio, Texas, 78213, United States
Clinical Site 15

Mayfield Heights, Ohio, 44124, United States
Clinical Site 16

New York, New York, 10023, United States
Clinical Site 2

Fremont, California, 94538, United States
Clinical Site 3

North Little Rock, Arkansas, 72117, United States
Clinical Site 4

Frisco, Texas, 75034, United States
Clinical Site 5

Birmingham, Alabama, 35244, United States
Clinical Site 6

Tampa, Florida, 33615, United States
Clinical Site 7

Palo Alto, California, 94063, United States
Clinical Site 8

Philadelphia, Pennsylvania, 19103, United States
Clinical Site 9

Tucson, Arizona, 85704, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.